229 related articles for article (PubMed ID: 35999618)
1. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
Takada K; Shimokawa M; Mizuki F; Takamori S; Takenaka T; Miura N; Shikada Y; Yoshizumi T
Eur J Med Res; 2022 Aug; 27(1):157. PubMed ID: 35999618
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
4. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yan X; Tian X; Wu Z; Han W
Front Oncol; 2020; 10():1671. PubMed ID: 33072551
[No Abstract] [Full Text] [Related]
5. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
6. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
[TBL] [Abstract][Full Text] [Related]
7. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
8. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
9. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
Li LX; Socinski MA; Kichenadasse G; Karapetis CS; Shahnam A; McKinnon RA; Rowland A; Hopkins AM; Sorich MJ
BMC Cancer; 2024 Mar; 24(1):379. PubMed ID: 38528478
[TBL] [Abstract][Full Text] [Related]
10. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
14. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
17. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
Peng S; Ying AF; Tai BC; Soo RA
Transl Lung Cancer Res; 2020 Aug; 9(4):1124-1137. PubMed ID: 32953491
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():732214. PubMed ID: 34557415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
